StressGen starts anal dysplasia Phase III

StressGen (TSE:SSB) started a 128-patient U.S. double-blind, placebo-controlled Phase III trial of HspE7 to treat anal dysplasia (AIN) caused by human papillomavirus (HPV). Clinical efficacy will be d...